
This AOP is licensed under a Creative Commons Attribution 4.0 International License.
Aop: 111
Title
Decrease in androgen receptor activity leading to Leydig cell tumors (in rat)
Short name
Graphical Representation
Point of Contact
Contributors
- Charles Wood
Status
Author status | OECD status | OECD project | SAAOP status |
---|---|---|---|
Under Development: Contributions and Comments Welcome | 1.29 | Under Development |
This AOP was last modified on June 04, 2021 12:31
Revision dates for related pages
Page | Revision Date/Time |
---|---|
Decreased, Androgen receptor activity | December 03, 2016 16:37 |
Decreased, Testosterone binding to androgen receptor (hypothalamus) | September 16, 2017 10:16 |
Increase, Hyperplasia (Leydig cells) | September 16, 2017 10:16 |
Increase, Leydig cell tumors | September 16, 2017 10:16 |
Increased, Luteinizing hormone (LH) | September 16, 2017 10:16 |
Decreased, Androgen receptor activity leads to Decreased, Testosterone binding to androgen receptor (hypothalamus) | December 03, 2016 16:37 |
Increase, Hyperplasia (Leydig cells) leads to Increase, Leydig cell tumors | December 03, 2016 16:37 |
Decreased, Testosterone binding to androgen receptor (hypothalamus) leads to Increased, Luteinizing hormone (LH) | December 03, 2016 16:38 |
Increased, Luteinizing hormone (LH) leads to Increase, Hyperplasia (Leydig cells) | December 03, 2016 16:38 |
Abstract
This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.
AOP Development Strategy
Context
Strategy
Summary of the AOP
Events:
Molecular Initiating Events (MIE)
Key Events (KE)
Adverse Outcomes (AO)
Type | Event ID | Title | Short name |
---|
MIE | 742 | Decreased, Androgen receptor activity | Decreased, Androgen receptor activity |
KE | 743 | Decreased, Testosterone binding to androgen receptor (hypothalamus) | Decreased, Testosterone binding to androgen receptor (hypothalamus) |
KE | 744 | Increase, Hyperplasia (Leydig cells) | Increase, Hyperplasia (Leydig cells) |
KE | 754 | Increased, Luteinizing hormone (LH) | Increased, Luteinizing hormone (LH) |
AO | 745 | Increase, Leydig cell tumors | Increase, Leydig cell tumors |
Relationships Between Two Key Events (Including MIEs and AOs)
Title | Adjacency | Evidence | Quantitative Understanding |
---|
Network View
Prototypical Stressors
Life Stage Applicability
Taxonomic Applicability
Term | Scientific Term | Evidence | Link |
---|---|---|---|
Rattus norvegicus | Rattus norvegicus | NCBI |
Sex Applicability
Sex | Evidence |
---|---|
Male |
Overall Assessment of the AOP
Domain of Applicability
Essentiality of the Key Events
Evidence Assessment
Known Modulating Factors
Quantitative Understanding
Considerations for Potential Applications of the AOP (optional)
References
Cook, J. C., Klinefelter, G. R., Hardisty, J. F., Sharpe, R. M., & Foster, P. M. (1999). Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. Crit Rev Toxicol, 29(2), 169-261. doi: 10.1080/10408449991349203